ArriVent BioPharma Inc [AVBP] stock is trading at $24.35, up 6.42%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AVBP shares have gain 5.64% over the last week, with a monthly amount glided 30.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ArriVent BioPharma Inc [NASDAQ: AVBP] stock has seen the most recent analyst activity on November 25, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $43. On March 20, 2025, B. Riley Securities initiated with a Buy rating and assigned a price target of $37 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $45 on March 10, 2025. Oppenheimer initiated its recommendation with an Outperform and recommended $35 as its price target on July 22, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on April 30, 2024, and assigned it a price target of $25. In a note dated February 20, 2024, Jefferies initiated a Buy rating and provided a target price of $35 on this stock.
ArriVent BioPharma Inc [AVBP] stock has fluctuated between $15.47 and $29.86 over the past year. Currently, Wall Street analysts expect the stock to reach $38 within the next 12 months. ArriVent BioPharma Inc [NASDAQ: AVBP] shares were valued at $24.35 at the most recent close of the market. An investor can expect a potential return of 56.06% based on the average AVBP price forecast.
Analyzing the AVBP fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.55 and Total Capital is -0.59. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.16 points at the first support level, and at 21.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.27, and for the 2nd resistance point, it is at 26.19.
Ratios To Look Out For
For context, ArriVent BioPharma Inc’s Current Ratio is 14.90. Also, the Quick Ratio is 14.90, while the Cash Ratio stands at 5.74.
